Application of rapamycin, an mTOR inhibitor, to the vascular compartment of the NVUs resulted in a significant decrease of the BMEC barrier permeabilities in TSC NVUs when compared to vehicle treated TSC NVUs, but did not affect BBB permeabilities in control NVUs (Fig. 7A, B). This evidence concerns the gene MTOR and tuberous sclerosis.